XLO Financial Statements | Balance Sheet, Income & Cash Flow Analysis
The financial statements for XLO (XLO) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| PDSB PDS Biotechnology Corporation | $1.34 +3.88% |
| FGEN FibroGen, Inc. | $9.07 -1.63% |
| KZR Kezar Life Sciences, Inc. | $7.28 -0.14% |
| L Loews Corporation | $111.49 +0.38% |
| LVTX LAVA Therapeutics N.V. | $1.74 -3.87% |
| SKYE Skye Bioscience, Inc. | $0.83 +5.32% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| PDSB PDS Biotechnology Corporation | $1.34 | +3.88% | 74.79 M | -1.81 | -0.74 | 0.00% | Buy | 899 |
| FGEN FibroGen, Inc. | $9.07 | -1.63% | 36.69 M | -0.71 | -12.85 | 0.00% | Hold | 29 |
| KZR Kezar Life Sciences, Inc. | $7.28 | -0.14% | 53.66 M | -0.95 | -7.66 | 0.00% | Hold | 58 |
| L Loews Corporation | $111.49 | +0.38% | 22.97 B | 13.99 | 7.97 | 0.11% | Hold | 478 |
| LVTX LAVA Therapeutics N.V. | $1.74 | -3.87% | 45.77 M | -2.00 | -0.87 | 0.00% | Hold | 286 |
| SKYE Skye Bioscience, Inc. | $0.83 | +5.32% | 27.54 M | -0.59 | -1.41 | 0.00% | Buy | 209 |
Frequently Asked Questions
What are XLO's latest financial results?
Review XLO's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has XLO's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is XLO's cash flow situation and liquidity?
Cash flow statements reveal how XLO generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does XLO's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether XLO is outperforming or lagging within its sector.
Are XLO's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether XLO's profits are repeatable and supported by strong fundamentals.